WEST PHARMACEUTICAL SVSC INC's gross profit margin for the second quarter of its fiscal year 2014 is essentially unchanged when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. WEST PHARMACEUTICAL SVSC INC has strong liquidity. Currently, the Quick Ratio is 1.97 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 24.02% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY14||Q2 FY13|
|Net Sales ($mil)||368.9||344.5|
|Net Income ($mil)||37.6||30.2|
|Balance Sheet||Q2 FY14||Q2 FY13|
|Cash & Equiv. ($mil)||226.7||198.1|
|Total Assets ($mil)||1704.7||1612.7|
|Total Debt ($mil)||361.5||394.8|
|Profitability||Q2 FY14||Q2 FY13|
|Gross Profit Margin||39.28||38.2|
|Return on Assets||6.75||6.06|
|Return on Equity||11.83||12.47|
|Debt||Q2 FY14||Q2 FY13|
|Share Data||Q2 FY14||Q2 FY13|
|Shares outstanding (mil)||70.8||69.4|
|Div / share||0.1||0.1|
|Book value / share||13.74||11.3|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||320428.0||273760.0|
BUY. The current P/E ratio indicates a discount compared to an average of 28.90 for the Health Care Equipment & Supplies industry and a premium compared to the S&P 500 average of 18.06. To use another comparison, its price-to-book ratio of 3.22 indicates a premium versus the S&P 500 average of 2.49 and a discount versus the industry average of 4.01. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, WEST PHARMACEUTICAL SVSC INC proves to trade at a discount to investment alternatives within the industry.
|WST 27.68||Peers 28.90||WST 16.08||Peers 20.83|
Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation.
WST is trading at a valuation on par with its peers.
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
WST is trading at a discount to its peers.
|WST 20.99||Peers 19.06||WST 1.55||Peers 0.88|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
WST is trading at a significant premium to its peers.
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
WST trades at a significant premium to its peers.
|WST 3.22||Peers 4.01||WST 14.69||Peers 53.00|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
WST is trading at a discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, WST is expected to significantly trail its peers on the basis of its earnings growth rate.
|WST 2.24||Peers 3.83||WST 6.95||Peers 5.90|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
WST is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
WST has a sales growth rate that exceeds its peers.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV